A leucemia, tipo de câncer que afeta as células sanguíneas e a medula óssea, conta com diversos tipos e é complexa de tratar, ...

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

Cientistas tentam superar a notória dificuldade em fazer o tratamento considerado revolucionário funcionar nesse cenário ...

"Cilta-cel is the first CAR T-cell therapy to demonstrate an overall survival benefit in multiple myeloma," María-Victoria ...

Estimular duas respostas imunológicas opostas pode aumentar a eficácia de tratamentos contra o câncer, revela estudo.

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to ...

HealthDay News — The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study published online ...

Researchers at UNIGE and HUG have created CAR-T cells that can selectively target malignant gliomas, sparing the surrounding healthy tissue. Glioblastoma is the most common and aggressive form of ...

Car-T cell therapy has changed the face of many cancer treatments, but the level of customization it requires still comes ...

Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.